Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Joseph Bonventre
Brigham and Women's Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Goldfinch Biopharma, Inc.
Payment for services (e.g., consulting fees, honoraria, paid authorship)
The research combines expertise in kidney biology, genetics, and tissue engineering to develop kidney disease models, kidney organoids, and advance the field of regenerative medicine. Dr. Bonventre is a co-founder of, and holds equity in, Goldfinch Biopharma, Inc., a company that seeks to integrate genetics and kidney biology to identify, validate, and pursue novel therapeutic targets for kidney disease. Because the grants involve making organoids, additional techniques or methods in the development of organoids could also be beneficial to Goldfinch in testing therapeutic compounds for toxicity and efficacy.
Kidney Microphysiological Analysis Platforms (MAP) to Optimize Function and Model Disease
Narrative The proposed work will take advantage of new technologies in stem cell biology, genome editing, microfabrication, microfluidics and bioprinting to model kidney diseases, and establish systems to test for drug development to test for efficacy and to screen for kidney toxicity using human tissue. We use stem cell made from patients with kidney disease and healthy individuals. We create or correct mutations that are present in humans with disease and then derive kidney cells and structures, organoids, in culture. The Bonventre, Lee and Lewis laboratories will incorporate these cells and structures into engineered devices to facilitate drug discovery and toxicity testing.
Filed on October 10, 2017.
Tell us what you know about Joseph Bonventre's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Joseph Bonventre filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Joseph Bonventre | Brigham and Women's Hospital | Conflict of Interest | Goldfinch Biopharma, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.